Floatz logo

Ctc-501

Depression

University of California, San FranciscoPhase 4 / ApprovedActive
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
73/ 100

Competitive context

90 Active assets in the Depression cohort.

Asset / SponsorPhaseRating
Opc-34712
Dr. Albert Kar-Kin Chung
Phase 4A
S-Ketamine
Janssen Korea, Ltd., Korea
Phase 4A
Paroxetine
GlaxoSmithKline
Phase 4BBB
Saredutant
Sanofi
Phase 3BBB
S-Ketamine
Chinese PLA General Hospital
Phase 4BBB

View all 50 →

Same molecule, other indications

Ctc-501 is also rated in:

Parkinson diseaseDormant
BBB
Indicative ·
72 / 100
View asset →
bipolar disorderDormant
BB
Indicative ·
68 / 100
View asset →
adrenoleukodystrophyDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →